SCHEMBL4061010

SCHEMBL4061010

O=C(c1cn(-c2ccc3ccccc3n2)c2ncccc12)C(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.50
RORC P51449 5/20 0.41
HTT P42858 1/20 0.40
PDE10A Q9Y233 1/20 0.37
HTR3A P46098 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
KDM4E B2RXH2 4/20 0.37
IDO1 P14902 1/20 0.36
PDE4A P27815 1/20 0.36
KCNH2 Q12809 1/20 0.36
CNR2 P34972 3/20 0.35
CYP2C9 P11712 2/20 0.35
ALDH1A1 P00352 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
CNR1 P21554 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4062265 0.86 NPC1 (0.45) RORCHTR3ANPC1RAB9AKDM4E
Hydrochloric Acid SCHEMBL4058504 0.84 HTR3A (0.40) RORCHTR3ANPC1RAB9AKDM4E
SCHEMBL4058546 0.80 ATM (0.53) ATMRORCHTTKDM4EIDO1
SCHEMBL4071018 0.79 ATM (0.52) ATMRORCHTTKDM4EIDO1
SCHEMBL4062258 0.78 HTR3A (0.41) HTR3ANPC1RAB9AKDM4EPDE4A
SCHEMBL31404665 0.72 HTT (0.60) ATMHTTHTR3AKDM4EIDO1
SCHEMBL21979497 0.72 HTT (0.60) ATMHTTHTR3AKDM4EIDO1
SCHEMBL4239984 0.68 NPC1 (0.49) RORCPDE10ANPC1RAB9AKDM4E
SCHEMBL4060456 0.68 CDC7 (0.59) HTTPDE10AHTR3ANPC1RAB9A
SCHEMBL4060213 0.67 HTR3A (0.54) RORCHTR3AKDM4EPDE4AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641791-B1 3-(GUANIDINOCARBONYL)HETEROCYCLE DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM SANOFI AVENTIS DEUTSCHLAND (DE) 2009-07-29 EP disclosed
US-7230007-B2 Derivatives of 3-(Guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-12 US disclosed
EP-1641791-A1 3-(GUANIDINOCARBONYL)HETEROCYCLE DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM Sanofi-Aventis Deutschland GmbH (DE) 2006-04-05 EP disclosed
US-20050014758-A1 Derivatives of 3-(guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-01-20 US disclosed
WO-2004111048-A1 3-(GUANIDINOCARBONYL)HETEROCYCLE DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014758-A1 Derivatives of 3-(guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom TNNI3, TNNT2, TNNC1 ATM 2939/4885RORC 1476/4885HTT 4335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.